The co-expression of CD39 and PD-1 endows these Tregs with potent suppressive capacity through adenosine-mediated and PD-1–dependent inhibitory pathways, promoting immune evasion, tumor progression, and resistance to immune checkpoint blockade (78). Here, ENTPD1 is linked to neoplasm.